Editas Medicine (EDIT) Reports Q4 Loss of $0.52/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update
February 28, 2019 4:01 PM ESTEDIT-101 for LCA10 set to be first ever in vivo CRISPR medicine administered to patients with dosing expected in second half of 2019
Advancing potentially best-in-class engineered cell medicine for
sickle cell disease and beta-thalassemia
Appointed Cynthia Collins and David Scadden, M.D., to Board of Directors
and named Collins as interim Chief Executive Officer
Year-end cash, cash equivalents, and marketable securities of $369 million expected to fund advancement of multiple transformative experimental medicines
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) --... More
